Projection into the future: combination of orphenadrine and diclofenac in patients with bone metastases
Introduction. Radiation therapy is an effective method of treating pain in patients with bone metastases, but during radiotherapy there is often an increase in pain. The presence of a new drug containing a combination of orphenadrine and diclofenac in oncologists expands the possibilities of analgesia.Aim. To evaluate the efficacy and safety of the use of a fixed combination of diclofenac and orphenadrine in patients with pain due to metastatic bone damage during radiotherapy.Materials and methods. The patients were randomized into two groups: the first group (n = 30) received the drug Neodolpasse intravenously once a day for two days; the second - 2 times a day (n = 30) - 2 days. Efficacy was evaluated based on the following measurements: intensity of pain by NRS immediately after administration of the drug, after 30 minutes, after 1, 2, 4 and 24 hours, the dynamics of daily doses of analgesics.Results and discussion. In group 1, a meaningful decrease in pain intensity (p < 0.05) from 48.7 ± 10.6 mm to 26.8 ± 10.7 mm was achieved 30 minutes after the completion of infusion. The pain intensity measured by the Numeric Rating Scale (NRS) reached its minimum value 2 hours after the completion of infusion (22.5 ± 12.0 mm). In group 2, the pain intensity decreased 30 minutes after the completion of infusion, a meaningful decrease (p < 0.05) in pain intensity was achieved from 56.5 ± 9.8 mm to 34.0 ± 10.5 mm, and up to 29.8 ± 10.2 mm after the second dose. The pain intensity decreased by 45.9% in group 1 and by 47.9% in group 2 towards the end of the Neodolpasse therapy cycle. During the study, two mild to moderate adverse events (nausea, drop in blood pressure) that did not require any significant drug therapy were observed.Conclusion. The results of the study confirm that the use of the drug according to the proposed method is a safe and effective way of treating pain syndrome during radiotherapy in patients with metastatic bone damage..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2022 |
|---|---|
| Enthalten in: |
Медицинский совет - (2022), 9, Seite 147-156 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
G. R. Abuzarova [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Bone metastases |
|---|
| doi: |
10.21518/2079-701X-2022-16-9-147-156 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ023211032 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ023211032 | ||
| 003 | DE-627 | ||
| 005 | 20230505014212.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2022 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.21518/2079-701X-2022-16-9-147-156 |2 doi | |
| 035 | |a (DE-627)DOAJ023211032 | ||
| 035 | |a (DE-599)DOAJ7abbcbd29df04b938f182e093f3d0842 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 0 | |a G. R. Abuzarova |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Projection into the future: combination of orphenadrine and diclofenac in patients with bone metastases |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Introduction. Radiation therapy is an effective method of treating pain in patients with bone metastases, but during radiotherapy there is often an increase in pain. The presence of a new drug containing a combination of orphenadrine and diclofenac in oncologists expands the possibilities of analgesia.Aim. To evaluate the efficacy and safety of the use of a fixed combination of diclofenac and orphenadrine in patients with pain due to metastatic bone damage during radiotherapy.Materials and methods. The patients were randomized into two groups: the first group (n = 30) received the drug Neodolpasse intravenously once a day for two days; the second - 2 times a day (n = 30) - 2 days. Efficacy was evaluated based on the following measurements: intensity of pain by NRS immediately after administration of the drug, after 30 minutes, after 1, 2, 4 and 24 hours, the dynamics of daily doses of analgesics.Results and discussion. In group 1, a meaningful decrease in pain intensity (p < 0.05) from 48.7 ± 10.6 mm to 26.8 ± 10.7 mm was achieved 30 minutes after the completion of infusion. The pain intensity measured by the Numeric Rating Scale (NRS) reached its minimum value 2 hours after the completion of infusion (22.5 ± 12.0 mm). In group 2, the pain intensity decreased 30 minutes after the completion of infusion, a meaningful decrease (p < 0.05) in pain intensity was achieved from 56.5 ± 9.8 mm to 34.0 ± 10.5 mm, and up to 29.8 ± 10.2 mm after the second dose. The pain intensity decreased by 45.9% in group 1 and by 47.9% in group 2 towards the end of the Neodolpasse therapy cycle. During the study, two mild to moderate adverse events (nausea, drop in blood pressure) that did not require any significant drug therapy were observed.Conclusion. The results of the study confirm that the use of the drug according to the proposed method is a safe and effective way of treating pain syndrome during radiotherapy in patients with metastatic bone damage. | ||
| 650 | 4 | |a oncology | |
| 650 | 4 | |a bone metastases | |
| 650 | 4 | |a pain management | |
| 650 | 4 | |a radiation therapy | |
| 650 | 4 | |a radiotion therapy-related complications | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a R. R. Sarmanaeva |e verfasserin |4 aut | |
| 700 | 0 | |a S. V. Kuznetsov |e verfasserin |4 aut | |
| 700 | 0 | |a N. M. Bychkova |e verfasserin |4 aut | |
| 700 | 0 | |a Yu. V. Brazhnikova |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Медицинский совет |d Remedium Group LLC, 2019 |g (2022), 9, Seite 147-156 |w (DE-627)DOAJ000029483 |x 26585790 |7 nnns |
| 773 | 1 | 8 | |g year:2022 |g number:9 |g pages:147-156 |
| 856 | 4 | 0 | |u https://doi.org/10.21518/2079-701X-2022-16-9-147-156 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/7abbcbd29df04b938f182e093f3d0842 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.med-sovet.pro/jour/article/view/6927 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2079-701X |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2658-5790 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |j 2022 |e 9 |h 147-156 | ||